AsymBio, the biologics-focused Contract Development and Manufacturing Organization (CDMO) under the Asymchem Group (stock codes: 002821.SZ / 6821.HK), has announced the groundbreaking of a new research and development facility at its Fengxian campus in Shanghai. This expansion represents a major milestone in enhancing the company's biologics CDMO capabilities while further establishing the Fengxian site as a key center for research, development, and manufacturing.
Construction commenced in May 2026, with completion and operational launch planned for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land and offer nearly 20,000 square meters of total floor space. Designed in accordance with green and low-carbon building principles, the facility will house capabilities for cell line development, upstream and downstream process development, conjugation process development, drug product development, and advanced analytical services.
Situated alongside AsymBio's existing clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs) at the Fengxian campus, the new R&D center will serve as a dedicated innovation hub. Its close integration with manufacturing operations is expected to improve technology transfer, facilitate efficient scale-up, and accelerate the transition from development to commercial production.
The facility will also host the AccPCC (Accelerated PCC Platform), an integrated research and development framework designed to reduce the time required to advance drug candidates from lead identification to preclinical candidate (PCC) selection. Leveraging AI-enabled, end-to-end workflows, the platform brings together early-stage research, Chemistry, Manufacturing and Controls (CMC), nonclinical evaluation, and early clinical translation. It offers comprehensive support in lead optimization, developability assessment, and customized early-stage CMC strategies for biotechnology companies worldwide.
Commenting on the initiative, AsymBio CEO Rui Yang emphasized that successful biologics development depends on early collaboration, integrated scientific and CMC decision-making, and consideration of manufacturability from the beginning of a project. By utilizing the combined R&D expertise available across the Asymchem Group, the AccPCC platform aims to enhance development efficiency, accelerate preclinical candidate selection, and shorten the journey from scientific discovery to clinical application.
The new Fengxian R&D building is expected to strengthen collaboration between research, process scale-up, and manufacturing, enabling clients to minimize development bottlenecks and manage complex biologics programs with greater efficiency and confidence.